中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1256 records (took 0.126 seconds)

    Wireless magnetic resonance device for optogenetic applications in animal model
    533.
    发明授权
    Wireless magnetic resonance device for optogenetic applications in animal model 有权

    公开(公告)号：US11471699B2

    公开(公告)日：2022-10-18

    申请号：US16593283

    申请日：2019-10-04

    Applicant: ACADEMIA SINICA ,  Fo Guang University

    Inventor： Bai-Chung Shyu ,  Arthur Chih-Hsin Tsai ,  Chih-Wei Huang

    IPC: A61N5/06 ,  A61B5/00 ,  A61B5/055 ,  G01R33/36 ,  A61K49/00 ,  A61N1/36 ,  A61N5/067

    Abstract: The present wireless remote control device is a type of equipment with non-tethered optical stimulation. The characteristic of this device is designed to utilize a magnetic resonance technique to modify the deficits of the conventional magnetic induction or radio-frequency power source. Compared to the other devices of photostimulation, the advantages are as follow: there is a strong and even electromagnetic power; the cost is cheaper than the previous others; the device uses the receiver coil on an animal's head to receive the magnetic power from the transformation of the electrical power in the outside big coil, and thus the weight of the receiver coil on the head is very light. The light and miniaturized coil on the head without battery could give animals more convenience in freely movement, and the behavior of animals can be controlled by the effective extent of the electromagnetic field through photostimulation.

    Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer
    536.
    发明授权
    Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer 有权

    公开(公告)号：US11357862B2

    公开(公告)日：2022-06-14

    申请号：US16062274

    申请日：2017-01-11

    Applicant: Academia Sinica

    Inventor： Han-Chung Wu ,  Chen-Yun Yeh

    IPC: A61K47/62 ,  A61K47/69 ,  A61K47/66 ,  A61P35/00 ,  A61K9/127 ,  A61K49/00 ,  A61K49/18 ,  C07K7/08 ,  A61K47/64

    Abstract: An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.

    COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA
    539.
    发明申请
    COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA 有权

    公开(公告)号：US20220152036A1

    公开(公告)日：2022-05-19

    申请号：US17439630

    申请日：2020-03-25

    Applicant: Academia Sinica ,  National Health Research Institutes

    Inventor： Weir-Torn JIAANG ,  Che-Kun James SHEN

    IPC: A61K31/52 ,  A61P7/06 ,  C07D473/16 ,  C07D473/18 ,  A61K31/5377

    Abstract: Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.

    Anti-TNF-alpha glycoantibodies and uses thereof
    540.
    发明授权
    Anti-TNF-alpha glycoantibodies and uses thereof 有权

    公开(公告)号：US11332523B2

    公开(公告)日：2022-05-17

    申请号：US14722775

    申请日：2015-05-27

    Applicant: Academia Sinica

    Inventor： Chi-Huey Wong ,  Chung-Yi Wu

    IPC: C07K16/24 ,  A61K39/395 ,  A61K45/06 ,  C12P21/00 ,  A61K39/00

    Abstract: The present disclosure relates to a novel class of anti-TNFα monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNFα IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNFα monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Patent Agency Ranking